Arrowhead's RNAi candidate outperforms rival in late-stage triglyceride studies
At the ESC 2026 meeting in Munich, Arrowhead presented results from two Phase 3 trials of its RNA interference drug Redemplo in patients with elevated triglycerides. The therapy demonstrated efficacy and a favorable safety profile compared to Ionis's competing treatment. These findings position Arrowhead to challenge Ionis in the triglyceride-lowering market.
Arrowhead Pharmaceuticals presented data from two late-stage trials at the ESC 2026 meeting in Munich, evaluating its RNA interference therapy Redemplo in patients with elevated triglycerides. The results showed meaningful efficacy alongside a favorable safety profile when measured against Ionis's competing drug. These findings strengthen Arrowhead's position in the triglyceride-lowering space.
The comparison with Ionis is notable, as both companies are pursuing similar patient populations. With positive late-stage data in hand, Arrowhead appears well-placed to gain ground in this market, potentially reshaping competitive dynamics as the therapy moves toward broader clinical adoption.
These results could give physicians a new option for managing elevated triglycerides, a condition tied to cardiovascular risk. If Redemplo reaches the market, patients may benefit from a therapy with a stronger efficacy or safety profile than existing alternatives. The competitive pressure could also influence pricing and access decisions. However, regulatory review and long-term real-world data remain uncertain, so the full impact on clinical practice will only become clear over time.